Recursion Pharmaceuticals

Recursion Pharmaceuticals LT Debt/Equity

The Long-Term Debt to Equity Ratio of Recursion Pharmaceuticals (RXRX) as of Oct 27, 2026 is 0.01. In the previous year, Long-Term Debt to Equity Ratio was 0.02 — a change of -53.99% (lower).

LT Debt/Equity

0.01

YoY

-53.99%

Last updated:

Long-Term Debt to Equity Ratio of Recursion Pharmaceuticals is 2025 0.01 . Long-Term Debt to Equity Ratio of Recursion Pharmaceuticals was 2024 0.02 . It decreases by -53.99% lower compared to the previous year.

The Recursion Pharmaceuticals LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2019
-0.10 USD
Jan 1, 2020
-0.06 USD
Jan 1, 2021
0.00 USD
Jan 1, 2022
0.00 USD
Jan 1, 2023
0.00 USD
Jan 1, 2024
0.02 USD
Jan 1, 2025
0.01 USD
The Recursion Pharmaceuticals LT Debt/Equity history
YEARLT Debt/EquityYoY
0.01-53.99%
0.02+673.77%
0.00+115.33%
0.00-5.37%
0.00-102.11%
-0.06-44.63%
-0.10—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Recursion Pharmaceuticals Stock analysis

What does Recursion Pharmaceuticals do? Recursion Pharmaceuticals, Inc. makes money by developing novel therapeutics through its Recursion Operating System (OS), which integrates automation, artificial intelligence, machine learning, and in vivo validation. The company focuses on discovering medicines using advanced technologies in biology, chemistry, automation, and computer science. Its clinical programs include REC-994, REC-2282, REC-4881, and REC-3964, with REC-994 being an orally bioavailable, superoxide scavenger small molecule for treating cerebral cavernous malformations. The company generates revenue from its platform and clinical development efforts, targeting biopharmaceutical partnerships and potential future drug sales. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, leveraging its Recursion Data Universe to map biological and chemical relationships. The Recursion Operating System (OS) enables the company to rapidly translate silico hypotheses into validated insights and novel chemistry through iterative loops of wet lab biology and chemistry data. The company's platform integrates physical and digital components to create virtuous cycles, driving the discovery of novel therapeutics. Revenue is derived from its technology platform and clinical programs, with potential partnerships in the biopharmaceutical sector. The company's primary products are its Recursion Operating System (OS) and clinical programs such as REC-994, REC-2282, REC-4881, and REC-3964. REC-994 is a small molecule designed for cerebral cavernous malformations, while the other programs are part of its broader therapeutic pipeline. The company targets biopharmaceutical companies and research institutions as potential partners for its technology and drug development services. Recursion Pharmaceuticals, Inc. monetizes its platform through licensing agreements and collaborative research deals, focusing on the discovery of novel medicines using AI-driven approaches. Recursion Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Recursion Pharmaceuticals stock

Long-Term Debt to Equity Ratio of Recursion Pharmaceuticals is 0.01 in 2025.

Long-Term Debt to Equity Ratio of Recursion Pharmaceuticals changed from 0.02 to 0.01, representing a -53.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio Recursion Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's Recursion Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Recursion Pharmaceuticals

All Key Metrics — Recursion Pharmaceuticals